We are live on ! Find out more
IFRX icon

InflaRx
IFRX

26 hedge funds and large institutions have $19.2M invested in InflaRx in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

30% more funds holding

Funds holding: 20 → 26 (+6)

1.04% less ownership

Funds ownership: 20.26% → 19.22% (-1%)

9% less capital invested

Capital invested by funds: $20.9M → $19.2M (-$1.78M)

70% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 10

Holders
26
Holders Change
+6
Holders Change %
+30%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
3
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$3.95M
2
Citadel Advisors
Citadel Advisors
Florida
+$1.65M
3
BC
Birchview Capital
Vermont
+$407K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$396K
5
Walleye Capital
Walleye Capital
New York
+$101K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$2.95M
2
SFM
Sphera Funds Management
Israel
-$1.31M
3
IBT
International Biotechnology Trust
United Kingdom
-$869K
4
EP
Eversept Partners
New York
-$515K
5
FIA
FNY Investment Advisers
New York
-$482K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$6.79M – – –
O
2
OrbiMed
New York
$4.08M +$3.95M +1,067,600 New
Citadel Advisors
3
Citadel Advisors
Florida
$2.11M +$1.65M +445,472 +421%
FIA
4
FNY Investment Advisers
New York
$1.41M -$482K -130,000 -26%
IC
5
Ikarian Capital
Texas
$1M -$358K -96,528 -27%
EP
6
Eversept Partners
New York
$747K -$515K -139,130 -42%
Goldman Sachs
7
Goldman Sachs
New York
$557K -$74.1K -20,000 -12%
BC
8
Birchview Capital
Vermont
$420K +$407K +110,000 New
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$408K +$396K +106,805 New
Morgan Stanley
10
Morgan Stanley
New York
$404K -$2.95M -796,564 -88%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$345K +$9.87K +2,664 +3%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$320K -$98.9K -26,700 -24%
BFM
13
Boothbay Fund Management
New York
$167K -$60.3K -16,273 -27%
Walleye Capital
14
Walleye Capital
New York
$104K +$101K +27,380 New
SSA
15
Schonfeld Strategic Advisors
New York
$82K +$79.9K +21,585 New
SIM
16
Spark Investment Management
New York
$71K +$69.6K +18,800 New
BlackRock
17
BlackRock
New York
$63K +$17.5K +4,721 +40%
CS
18
Credit Suisse
Switzerland
$40K +$38.7K +10,445 New
Bank of America
19
Bank of America
North Carolina
$29K +$28.5K +7,691 New
UBS Group
20
UBS Group
Switzerland
$9K +$8.83K +2,385 New
TWA
21
TCI Wealth Advisors
Arizona
$3K +$2.96K +800 New
TRCT
22
Tower Research Capital (TRC)
New York
$1K -$36.7K -9,912 -97%
SFM
23
Sphera Funds Management
Israel
– -$1.31M -330,000 Closed
IBT
24
International Biotechnology Trust
United Kingdom
– -$869K -220,000 Closed
Millennium Management
25
Millennium Management
New York
– -$475K -120,070 Closed
1
2

IFRX Hedge Fund Activity: Q1 2020 in Review

26 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q1 2020, worth a combined $19.2M — down 8.5% from $20.9M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new IFRX positions and 6 closed out — a net gain of 6 holders — while 3 added to existing stakes and 10 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $3.95M. The largest seller was Morgan Stanley, cutting an estimated $2.95M.

  • 26 institutional investors held InflaRx (IFRX) as of Q1 2020, up from 20 in Q4 2019.
  • Funds reported $19.2M of InflaRx stock for Q1 2020, down 8.5% quarter-over-quarter.
  • 12 funds opened new InflaRx positions in Q1 2020 and 6 closed out, a net change of +6 holders.
  • The largest InflaRx buyer in Q1 2020 was OrbiMed, an estimated $3.95M added.
  • The largest InflaRx seller in Q1 2020 was Morgan Stanley, an estimated $2.95M sold.

Based on aggregated 13F filings for Q1 2020.